Quality crisis worsens for Indian generics

First the UK regulator warned about “rogue” Wockhardt co-codamol that contained too much codeine. Now the MHRA has banned imports to Europe from one of the company’s Indian sites and so has the (US) FDA. Wockhardt has transferred production from the troubled Maharahtra facility and continues to supply Europe from other plants in India and its facilities in the UK. This did not stop the Business Standard from proclaiming that Wockhardt had been “banned in Europe”. This is the latest in a series of confidence-crippling crises for India’s generics firms and India’s troubled central and state regulators.